

<b>Reference:</b>	FOI.20358.26
<b>Subject:</b>	Biologics in Rheumatology
<b>Date of Request:</b>	5 May 2026

**Requested:**

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Apremilast [Generic]
- Baricitinib [Olumiant]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Golimumab Biosimilar
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tocilizumab Biosimilars
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]
- Ustekinumab Biosimilar

**Response:**

Hywel Dda University Health Board (UHB) provides within the table below, the number of patients treated by the Rheumatology Department with the listed biologic medicines, during the period 1 February to 30 April 2026.

<b>Medicine</b>	<b>Number</b>
Abatacept [Orencia]	104
Adalimumab [Humira]	12
Adalimumab Biosimilars	342
Apremilast [Otezla]	25
Apremilast [Generic]	0

Baricitinib [Olumiant]	40
Bimekizumab [Bimzelx]	7
Certolizumab [Cimzia]	38
Etanercept [Enbrel]	18
Etanercept Biosimilars	151
Filgotinib [Jyseleca]	19
Golimumab [Simponi]	23
Golimumab Biosimilar	0
Guselkumab [Tremfya]	0
Infliximab [Remicade]	0
Infliximab Biosimilars	16
Ixekizumab [Taltz]	5
Risankizumab [Skyrizi]	5
Rituximab [MabThera]	0
Rituximab Biosimilars	27
Sarilumab [Kevzara]	10
Secukinumab [Cosentyx]	67
Tocilizumab [Ro Actemra]	68
Tocilizumab Biosimilars	15
Tofacitinib [Xeljanz]	7
Upadacitinib [Rinvoq]	33
Ustekinumab [Stelara]	0
Ustekinumab Biosimilar	14